Non-insulin-dependent diabetes mellitus (NIDDM) is one of the most commonmetabolic and endocrine disorders in developed countries. NIDDMis a multifactorial disorder in which genetic factors play a complex role in its development. Until recently, little has been known of the genetic determinants ofNIDDM.Advances in molecular biological and molecular genetic approaches have now made it possible to begin to identify the diabetes susceptibility genes in NIDDM. This review describes the progress of recent research in the molecular genetic aspects of NIDDM. (Internal Medicine 35: 347-355, 1996) 
affecting 5-10% of the population in developed countries (1) . NIDDM is characterized by impaired insulin secretion, increased basal hepatic glucose production, and peripheral insulin resistance in skeletal muscle and adipose tissue (2) , but there is controversy as to which defect is primary. Somestudies suggest that insulin resistance is the earliest detectable defect in the course of this disease (3) (4) (5) , while others emphasize the role of abnormal p-cell function (6) (7) (8) (9) . NIDDMis a multifactorial disorder with polygenie inheritance and multiple environmental factors contributing to its development ( 10). Evidence of the importance of genetic factors in the development of NIDDM comesfrom concordance studies of NIDDM in identical (monozygotic) and nonidentical (dizygotic) twin pairs and its frequency in first-degree relatives of affected individuals ( 1 1-14) . In NIDDM,the concordance in monozygotic twin pairs is less than 100%, indicating that nongenetic factors also play an important role in the etiology of NIDDM (1) . Although twin, family, and population studies show that genetic susceptibility is an important determinant of NIDDM, it is evident that NIDDMis a genetically heterogeneous disorder. Several models have been proposed to explain the genetic contribution to NIDDM (15) (Fig. 1) . Within individuals, the single-gene model is applied to subtypes of NIDDM such as maturity-onset diabetes of the young (MODY),which has a single autosomal dominant trait (16). Another model suggests that major genes together with several minor modifying genes represent the genetic basis for the development of NIDDM.A third model suggests that a numberof different genes contribute to the development of NIDDM.Within a population, there are two models. In the first, several major genes account for a significant part of the cause of NIDDM. In the second, various different genes are responsible.
Approaches to identify the NIDDMsusceptibility genes Several approaches have been used to identify the genes of susceptibility to NIDDM.
Population-based studies and family-based studies In population-based association studies (17, 18), the frequency of a marker, which is often a candidate gene, is compared between affected and normal subjects. If NIDDMis found to be associated with a marker more frequently than expected by chance alone, a causal relationship between the genetic variation in the marker or a locus in linkage disequilibrium with the marker and NIDDM is suggested. However, there are other explanations for positive findings (false positive results), due to population stratification and epistasis (a functional association between two loci). Also, false negative results occur when the study is insufficient to detect a difference. Despite these limitations, population association studies to identify disease-susceptibility genes are able to detect subtle genetic effects on disease susceptibility and may detect loci that are unlikely to be identified in family studies. Twomethods of family-based study are used for the identification of diabetes-susceptibility genes: linkage studies and studies of affected relative pairs (1 9, 20 (one is a postulated disease-susceptibility locus, the other a marker locus at a knowngenomic location) are rarely separated by recombination and that they locate close together in the genome. However, linkage studies be cannot as readily applied in the analysis of the genetics of complex disorders, such as the commonforms ofNIDDM,as they are in a simple monogenetic diabetes such as MODY, which shows early onset and autosomal dominant inheritance (16). However, it is also possible to simplify studies of the genetics of complex disorders by analysis of only affected members of families. One, which has been widely used, is analysis of affected sib-pairs (19, 20) . This involves studying affected sibs in a pedigree to see how frequently a particular copy of a chromosomeregion is shared identical-by-descent (IBD), that is, inherited from a common ancestor within the pedigree. This methodrequires no information of modeof inheritance, allele frequencies, or penetrance in advance. The affected sib-pair analysis has been used successfully in complex diseases such as hypertension and insulindependent diabetes mellitus (IDDM) (26). However, at least 300 affected relative pairs are thought to be required to find loci linked to disease. Insulin exerts multiple effects on the cells of target tissues.
Although many signaling pathways are involved in the insulin actions, understanding the molecular mechanisms by which insulin stimulates glucose transport in muscle and adipose . IRS-1 binds to several proteins containing src homology 2 (SH2) domains, one of which is the p85 subunit of phosphatidyl inositol (PI)-3-kinase (37). PI-3 kinase, a heterodimeric protein is comprised of a catalytic p 1 10 subunit and a regulatory p85 subunit is a likely candidate in the signaling pathway of translocation of the glucose transporter isoform GLUT4,which is responsible for insulin-stimulated glucose transport in muscle and adipose tissue (38, 39). Accordingly, the genes whose products are involved in insulin actions, especially involved in signaling pathways in GLUT4transloca-tion, make good candidates for NIDDM susceptibility genes. Another approach currently used to identify NIDDMsusceptibility genes is "positional cloning" (27). When candidate genes have not been localized on the genomeor it is not known which gene may be involved in a disease, the positional cloning (also referred to as "reverse genetics") approach can be used to Genomicinformation obtained from rodent models may also be applied to the human genome: human chromosomal regions syntenic with regions thought to be NIDDMsusceptibility genes in rodent models of NIDDMwould be good candidates. A good example is the obese gene (ob gene) recently cloned from the ob/ob mouse (42). The ob gene was cloned by the positional cloning method and, subsequently, its human homolog also was isolated by homology screening. The genetic information obtained by "mRNAdifferential display" (43) may also be helpful in selecting candidates for human NIDDMsusceptibility genes.
The NIDDMsusceptibility genes Despite the extensive effort using all these methods, only a small fraction of the NIDDMsusceptibility genes has been identified to date.
Insulin gene
The human insulin gene is located near the short arm end of chromosome ll in band pl5.5 and has 3 exons (44, 45).
Although defects in the insulin/proinsulin molecule could influence insulin biosynthesis, processing, and regulated secretion as well as the biological potency of insulin, almost all NIDDM patients have structurally normal insulin/proinsulin. Mutations in the insulin gene so far have been reported in less than ten families (46, 47). Thus, an insulin/proinsulin mutation would seem to be a rare cause of NIDDM in most populations the basis of the mechanism by which they impair insulin receptor function (58): 1) impaired receptor biosynthesis, 2) impaired transport of receptors to the cell surface, 3) decreased affinity of insulin binding, 4) impaired tyrosine kinase activity, and 5) accelerated receptor degradation. Patients with insulin resistance due to mutations in the extracellular domain of the insulin receptor are genetic compounds or homozygous for the same mutation. By contrast, most of the patients with insulin resistance due to a mutation in the tyrosine kinase domain also express normal insulin receptors, suggesting that these mutations appear to act as a dominantnegative mutation. The contribution of mutations in the insulin receptor gene to the common forms of NIDDM is unknown. Taylor (b) MODY2 gene (glucokinase gene). Glucokinase (ATP: Dglucose-6-phosphotransferase), expressed exclusively in pancreatic islets and liver, catalyzes the first step of glycolysis, regulating the insulin secretion in response to glucose in pancreatic (3-cells and the uptake of glucose in the liver (33) . In contrast to other hexokinases, it has a high Kmvalue and is not inhibited by glucose-6phosphate. Rates of glucose phosphorylation vary with glucose levels, suggesting that glucokinase acts as a "glucose sensor" (33) . The humanglucokinase gene is composedof 12 exons spanning a region of more than 50 kbp of chromosome band 7pl3 (59) (60) (61) . It has two tissue-specific promoters, one of which is active in pancreatic (3-cells and the other in liver (62) (63) (64) . Linkage between the glucokinase gene and diabetes was first reported in French families with MODY (65) , and, subsequently, mutations of the glucokinase gene have been shown to be the cause of MODY (66) . Almost 30 different mutations have been identified in the glucokinase gene in diabetes mellitus (67, 68) . The majority of the mutations have been found in MODY. They also have been found in gestational diabetes mellitus (69, 70) and in late-onset NIDDM (71) (72) (73) . Glucokinase mutations have been identified in exons 2-10, with the majority being clustered in exons 5, 7, and 8. All of the glucokinase mutations associated with MODY result in reduced enzymatic activity with a decreased Vmaxand/or increase Kmfor glucose (74) . Since glucokinase is a monomer, it seems unlikely that the mutant glucokinase acts as a dominant negative mutation. Rather, a gene-dosage mechanismis the most likely explanation for a dominantly inherited form of diabetes caused by glucokinase mutation. It has been estimated that a 15%decrease in glucokinase activity could shift the threshold for glucose-stimulated insulin secretion form 5 to 6 mMglucose (33). Although glucokinase mutations are a major cause of MODY, at least in the French families, screening for mutations in NIDDMpatients indicates that the glucokinase gene is unlikely a major susceptibility gene for the common late-onset NIDDM. The glucokinase gene is nowreferred to as the "MODY2" gene. Mitochondrial DNA Several syndromes caused by point mutations, deletions, or duplications of mitochondrial DNA(mt DNA)are characterized by a decrease of oxidative phosphorylation and are associated with diabetes (75, 76) . It has recently been reported that a single mutation (G for A at nucleotide 3243, A3243 mutation) in the mt DNAfor the tRNALeuis cosegregated with diabetes and deafness in patients having maternally inherited diabetes (77, 78) . The cause of the diabetes is thought to be probably a chronic failure of oxidative phosphorylation in the pancreatic p-cells, leading to impaired insulin secretion. Screening of mt DNAmutations in Japanese NIDDMpatients has suggested that approximately 1 %of NIDDM in Japan may be associated with the A3243mutation (79) . The same mutation is also found in patients with MELAS(mitochondrial myeloencephalopathy lactic acidosis stroke-like episodes) syndrome, a neuromuscular disease accompanied by deafness and diabetes. Although the reason for the differences in phenotypic expression between MELAS and diabetes with deafness is unknown, it mightbe due to the varying degree of heteroplasmy in the different tissues.
Other candidates for NIDDMsusceptibility genes (a) The susceptibility genes of/5-cell dysfunction The glucose transporter GLUT2,having a high Kmfor glucose, is expressed predominantly in pancreatic P-cells and liver, and is thought to be involved, in part, with glucosesensing in insulin secretion (80) (81) (82) . Defects in the GLUT2
Internal Medicine Vol. 35, No. 5 (May 1996) gene, therefore, could lead to glucose-sensing abnormalities in pancreatic P-cells and/or abnormal glucose release from the liver. However, in genetic studies of GLUT2no significant mutations in most patients with NIDDMhave been found (83, 84) , suggesting that the GLUT2gene is not a susceptibility gene for the commonforms of NIDDM.
The voltage-dependent calcium channels in pancreatic (icells are the major pathway of the increase in intracellular calcium in response to glucose, the primary signal for insulin secretion. Therefore, they are a candidate gene for susceptibility to NIDDM (85, 86) . Recently, we have identified the p-cell ATP-sensitive K+ (KATP) channel (87), a key molecule linking glucose metabolism to the membrane potential of p-cells. The Amylin (islet amyloid peptide) is a 37 ammoacid peptide (88, 89) and is shown to be cosecreted with insulin from pancreatic P-cells (90) . Since amylin is the major protein component of islet amyloid seen in pancreatic islets ofNIDDM patients , the deposition of which maycontribute to the impaired p-cell function in NIDDM, a primary defect of the amylin gene has been postulated. However, several studies have failed to detect any mutations in NIDDMpatients, indicating that a primary structural abnormality of amylin or its precursor is not responsible for the formation of the islet amyloid seen in NIDDM patients (91, 92) . Other candidates are the genes for the receptors for hormones called "grucoincretins" such as GLP-1 (93) and GIP (94) , since these hormones have strong potentiating effects on glucose-induced insulin secretion (95) , defects in these receptors at the level ofpancreatic p-cells might lead to impaired glucoseinduced insulin secretion.
(b) The susceptibility genes of insulin resistance The insulin-responsive glucose transporter GLUT4is responsible for insulin-stimulated glucose uptake into fat and muscle (35 , 96) . Defects in GLUT4activity or expression could account for the defective glucose transport into these tissues which is seen in NIDDM.However, a genetic study of GLUT4 failed to reveal significant mutations in most patients with NIDDM(97), suggesting that a genetic abnormality of GLUT4 is unlikely the cause of the commonforms of NIDDM. Glycogen synthase is one of the target enzymes of insulin and its activity has been found to be reduced in patients with NIDDM (98, 99 Recently, the obese gene (ob gene) has been cloned (42). The expression of the obese gene product, called "leptin", is thought to be a signaling factor regulating body weight homeostasis and energy balance (107) (108) (109) . Since obesity is an important factor that predisposes to NIDDM, it will be interesting to learn how the ob gene contributes to the development of NIDDM with obesity. A genetic variation of the (33-adrenergic receptor (replacement of tryptophan by arginine at position 64) is also thought to be associated with obesity (1 10-1 12). 
